Drugs Affecting Blood and Blood Formation Practice Questions

Q: A 58-year-old woman had a mitral valve replacement, and was placed on anticoagulants and prophylactic antibiotics following her surgery. Five days after her surgery, she developed a sharply demarcated, erythematous rash on her left thigh. Two days after the rash appeared, large hemorrhagic bullae began to form in the area of the rash. Which of the following medications most likely caused the patient's rash?

Warfarin. ***Warfarin*** - The rash described, with sharply demarcated erythema, followed by hemorrhagic bullae, is highly suggestive of **warfarin-induced skin necrosis**. This rare but severe complication typically occurs in the first few days of therapy. - Warfarin blocks vitamin K-dependent clotting factors (II, VII, IX, X) and also protein C and S. Initial decrease in protein C, which has a shorter half-life, leads to a transient hypercoagulable state and microvascular thrombosis, causing skin necrosis in susceptible individuals. *Cefazolin* - **Cefazolin** is a cephalosporin antibiotic. While antibiotics can cause various skin reactions, including generalized rashes or Stevens-Johnson syndrome, it is not typically associated with localized, sharply demarcated hemorrhagic bullae as seen in this case. - **Allergic reactions** to cefazolin usually manifest as urticaria, maculopapular rash, or anaphylaxis, lacking the specific progression to hemorrhagic necrosis. *Aspirin* - **Aspirin** is an antiplatelet agent. Adverse skin reactions to aspirin are uncommon but can include urticaria, angioedema, or aspirin-exacerbated respiratory disease. - It does not characteristically cause **hemorrhagic bullae** or skin necrosis. Its mechanism of action primarily inhibits platelet aggregation, not coagulation factors that would lead to such necrotizing lesions. *Heparin* - **Heparin-induced thrombocytopenia (HIT)** is a well-known complication of heparin, which can lead to thrombotic events, but typically presents with new thrombosis and a drop in platelet count, not localized hemorrhagic bullae or skin necrosis as the primary dermatological manifestation. - **Heparin-induced skin lesions** usually occur at injection sites and often appear as erythematous, pruritic plaques or necrotic lesions only in the context of HIT with associated thrombosis, which differs from the presentation given.

Q: Arrange the following anticoagulant drugs in ascending order (shortest to longest) based on the pre-operative cessation time before surgery: 1) Clopidogrel 2) Ticlopidine 3) Low molecular weight heparin 4) Warfarin

3>4>1>2. ***3>4>1>2*** - The correct order, in ascending time from last dose to surgery, is **low molecular weight heparin (LMWH)** (12-24 hours), **warfarin** (5 days), **clopidogrel** (5-7 days), and **ticlopidine** (10-14 days). - This order reflects the varying half-lives and durations of action of these anticoagulants and antiplatelet agents. *2>1>3>4* - This order is incorrect as it places **ticlopidine** (longest withdrawal) before **clopidogrel** despite ticlopidine having a much longer recommended withdrawal period. - It also misplaces **LMWH** and **warfarin** in relation to the antiplatelet agents. *4>3>2>1* - This order incorrectly positions **warfarin** (5 days) as having the longest pre-surgical hold time, though it is shorter than ticlopidine and clopidogrel. - It also improperly orders the antiplatelets and **LMWH** with regard to their pre-operative cessation periods. *3>4>2>1* - This order incorrectly places **ticlopidine** after **clopidogrel**, when ticlopidine requires a significantly longer cessation period prior to surgery. - It correctly places **LMWH** and **warfarin** relative to each other, but the antiplatelet order is wrong.

Q: Haemaccel contains -

Degraded gelatin. ***Degraded gelatin (Polygeline)*** - **Haemaccel** is a plasma volume expander that primarily consists of **degraded gelatin polypeptides (polygeline)**. - These polypeptides help to increase the **colloid osmotic pressure** of the blood, drawing fluid into the intravascular space to restore circulating volume. - This is the **main active ingredient** responsible for its volume-expanding properties. *Calcium* - While Haemaccel formulation does contain **calcium chloride** as an electrolyte, it is **not the primary active component**. - Calcium is present to maintain electrolyte balance but does not contribute to the volume-expanding effect. - The key distinguishing feature is that degraded gelatin provides the colloid osmotic effect. *Albumin* - **Albumin** is a natural plasma protein and a common component of other colloid solutions, but it is **not present in Haemaccel**. - Albumin solutions are distinct colloid preparations (e.g., human albumin 5% or 20%) used for volume expansion. - Haemaccel uses synthetic gelatin polypeptides instead of natural albumin. *Sodium* - **Sodium chloride** is present in Haemaccel as an accompanying electrolyte for maintaining osmotic balance, but it is **not the main active component**. - The primary volume-expanding agent is degraded gelatin, not sodium. - Sodium provides isotonicity but not the colloid osmotic pressure needed for volume expansion.

Q: Warfarin induced skin necrosis is seen in?

Protein C deficiency. ***Protein C deficiency*** - **Warfarin-induced skin necrosis** occurs due to an initial paradoxical hypercoagulable state caused by the rapid decline of **Protein C**, a natural anticoagulant. - Individuals with **pre-existing Protein C deficiency** are at a higher risk because their baseline levels of this protective anticoagulant are already low. *Protein S deficiency* - Similar to Protein C, **Protein S** is a vitamin K-dependent anticoagulant that works with Protein C. - While Protein S deficiency can also increase the risk of thrombosis, Protein C deficiency is the more direct and common cause of warfarin-induced skin necrosis due to its rapid decline. *Antithrombin III deficiency* - **Antithrombin III** is a crucial inhibitor of thrombin and other coagulation factors, and its deficiency leads to an increased risk of venous thromboses. - However, Antithrombin III deficiency does not directly explain the specific mechanism of warfarin-induced skin necrosis, which is primarily linked to the Protein C pathway. *Hemophilia* - **Hemophilia** is a genetic bleeding disorder characterized by a deficiency in clotting factors VIII or IX, leading to impaired blood clot formation. - It is a bleeding disorder, not a thrombotic disorder, and therefore does not predispose to warfarin-induced skin necrosis; in fact, warfarin would typically be contraindicated due to bleeding risk.

Q: Oral factor Xa inhibitor is:

Rivaroxaban. ***Rivaroxaban*** - **Rivaroxaban** is a direct oral anticoagulant (DOAC) that specifically inhibits **factor Xa**, preventing thrombin generation and clot formation. - It is administered **orally** and is widely used for preventing and treating venous thromboembolism and stroke in atrial fibrillation. *Bivalirudin* - **Bivalirudin** is a **direct thrombin inhibitor** (DTI), not a factor Xa inhibitor. - It is administered **intravenously**, primarily used in percutaneous coronary interventions. *Dabigatran* - **Dabigatran** is an **oral direct thrombin inhibitor** (DTI), which directly inhibits thrombin (factor IIa). - It does not inhibit factor Xa; its mechanism of action is distinct from that of factor Xa inhibitors. *Fondaparinux* - **Fondaparinux** is an **indirect factor Xa inhibitor** that requires antithrombin for its anticoagulant activity. - It is administered **subcutaneously**, distinguishing it from oral factor Xa inhibitors like rivaroxaban.

Q: Coagulation testing is needed for:

Lepirudin (direct thrombin inhibitor). ***Lepirudin (direct thrombin inhibitor)*** - **Lepirudin**, being a direct thrombin inhibitor, necessitates **coagulation testing** (such as aPTT) to monitor its anticoagulant effect and adjust dosing, especially in patients with renal impairment. - Its narrow therapeutic window and potential for bleeding complications require careful monitoring to ensure patient safety and drug efficacy, as it lacks a specific antidote. *Dabigatran (oral anticoagulant)* - **Dabigatran** is a **direct oral anticoagulant (DOAC)** that typically does not require routine coagulation monitoring due to its predictable pharmacokinetic and pharmacodynamic profiles. - While specific tests can assess its effect in emergencies, they are not part of standard management, distinguishing it from drugs requiring regular monitoring. *Enoxaparin (low molecular weight heparin)* - **Enoxaparin**, a **low molecular weight heparin (LMWH)**, usually does not require routine coagulation monitoring in most patients due to its predictable dose-response relationship. - Monitoring with anti-Xa levels may be considered in specific populations, such as those with renal insufficiency, extremes of weight, or in pediatric and pregnant patients. *Fondaparinux (synthetic pentasaccharide)* - **Fondaparinux** is a synthetic pentasaccharide that **does not require routine coagulation monitoring** as its anticoagulant effect is highly predictable and dose-dependent. - Its action is mediated through selective inhibition of **Factor Xa**, and standard coagulation tests like aPTT or PT are not sensitive to its effects.

Q: All are used in management of overdosage of Fibrinolytics except?

DDAVP. ***DDAVP*** - **DDAVP (Desmopressin)** is primarily used to treat certain bleeding disorders like **von Willebrand disease** and **hemophilia A** by increasing factor VIII and von Willebrand factor. - It does not directly counteract the fibrinolytic activity or mechanisms involved in **fibrinolytic overdose**. *Epsilon amino Caproic Acid* - **Epsilon aminocaproic acid (EACA)** is an **antifibrinolytic agent** that inhibits plasminogen activation, thus preventing the breakdown of fibrin clots. - It is often used to treat bleeding due to hyperfibrinolysis, including that caused by **fibrinolytic overdose**. *Tranexamic Acid* - **Tranexamic acid (TXA)** is another potent **antifibrinolytic agent** that works by reversibly blocking lysine binding sites on plasminogen, preventing its conversion to plasmin. - It is frequently used to manage and prevent excessive bleeding, including in situations of **fibrinolytic overdose**. *FFP* - **Fresh frozen plasma (FFP)** contains all coagulation factors, including **fibrinogen** and other factors consumed or degraded during fibrinolytic therapy. - It is used to replenish clotting factors and improve hemostasis, making it a critical component in managing severe bleeding from **fibrinolytic overdose**.

Q: Which of the following drugs is used for treatment of cancer associated thromboembolism?

LMW heparin. ***LMW heparin*** - **Low molecular weight heparin (LMWH)** is the **preferred anticoagulant for cancer-associated thrombosis** due to its superior efficacy. - It has a more predictable pharmacokinetic profile compared to unfractionated heparin and is administered subcutaneously. *Direct factor Xa inhibitors* - While effective for general venous thromboembolism (VTE) treatment, some direct oral anticoagulants (DOACs) like factor Xa inhibitors (e.g., rivaroxaban, apixaban) may be considered but have shown mixed results in comparative studies with LMWH for cancer patients, especially those with gastrointestinal cancers, presenting a **higher risk of major bleeding**. - **LMWH** remains the **first-line choice**, especially in patients with active cancer, given the evidence for its greater efficacy and safety profile in this specific population. *Warfarin* - **Warfarin** is generally **not recommended** as a first-line treatment for cancer-associated thromboembolism due to its **drug interactions**, need for frequent monitoring (INR), and slower onset of action. - Patients with cancer often have fluctuating nutritional status, hepatic dysfunction, and receive other medications that can significantly impact warfarin's effectiveness and safety. *Anti-thrombin III inhibitors* - **Antithrombin III inhibitors** (e.g., antithrombin concentrate) are primarily used in specific conditions like **hereditary antithrombin deficiency** or in cases of heparin resistance. - They are **not a standard treatment** for cancer-associated thromboembolism in the general population of cancer patients.

Q: A patient with atrial fibrillation is prescribed warfarin. What is the PRIMARY factor that requires the most frequent monitoring to assess warfarin's anticoagulant effect?

INR (International Normalized Ratio). ***INR (International Normalized Ratio)*** - The **INR** is the most crucial test for monitoring **warfarin's anticoagulant effect**, reflecting the activity of the extrinsic coagulation pathway. - Regular monitoring ensures the patient's **INR** remains within the therapeutic range (typically 2.0-3.0 for atrial fibrillation) to prevent both thrombotic events and bleeding complications. *Liver function* - While relevant for assessing overall liver health and **warfarin metabolism**, liver function tests are not the primary, most frequent monitoring parameter for its **anticoagulant effect**. - **Warfarin** is metabolized in the liver, but routine, frequent monitoring of liver enzymes (e.g., ALT, AST) is not prioritized over **INR** for dose adjustments. *Potassium levels* - **Potassium levels** are not directly affected by **warfarin** and are not used to assess its anticoagulant efficacy or guide dosing. - Electrolyte imbalances, including potassium, are generally assessed for other medical conditions or drug side effects. *Blood pressure monitoring* - **Blood pressure** is important for overall cardiovascular health and to assess bleeding risk, particularly in patients on anticoagulants. - However, it does not directly measure the **anticoagulant effect** of **warfarin** on clotting factors.

Q: A 32-year-old woman is diagnosed with iron deficiency anemia and is prescribed oral iron supplementation. Which form of iron is most commonly prescribed for oral administration?

Ferrous sulfate. ***Ferrous sulfate*** - **Ferrous sulfate** is the **most commonly prescribed** oral iron supplement worldwide due to its excellent bioavailability, proven efficacy, and low cost. - It contains approximately **20% elemental iron** and is readily absorbed in the duodenum and proximal jejunum. - Its long-standing use, extensive clinical experience, and cost-effectiveness make it the **first-line choice** for treating iron deficiency anemia. *Ferric citrate* - **Ferric citrate** is a ferric (Fe³⁺) form with **lower bioavailability** compared to ferrous (Fe²⁺) salts. - It is primarily used as a **phosphate binder** in patients with chronic kidney disease rather than as a first-line treatment for iron deficiency anemia. *Iron dextran* - **Iron dextran** is an **intravenous iron preparation** and is not suitable for oral administration. - It is reserved for patients with severe iron deficiency, intolerance to oral iron, malabsorption syndromes, or when rapid iron repletion is needed. *Ferrous fumarate* - **Ferrous fumarate** is also an effective oral iron supplement containing approximately **33% elemental iron** (higher than ferrous sulfate). - It has comparable bioavailability and efficacy to ferrous sulfate. - While equally effective, **ferrous sulfate** remains more commonly prescribed due to lower cost and greater availability in most healthcare settings.

Question 1

A 58-year-old woman had a mitral valve replacement, and was placed on anticoagulants and prophylactic antibiotics following her surgery. Five days after her surgery, she developed a sharply demarcated, erythematous rash on her left thigh. Two days after the rash appeared, large hemorrhagic bullae began to form in the area of the rash. Which of the following medications most likely caused the patient's rash?

Accepted Answer

Warfarin

Answer

Cefazolin

Answer

Aspirin

Answer

Heparin

Question 2

Arrange the following anticoagulant drugs in ascending order (shortest to longest) based on the pre-operative cessation time before surgery: 1) Clopidogrel 2) Ticlopidine 3) Low molecular weight heparin 4) Warfarin

Accepted Answer

3>4>1>2

Answer

2>1>3>4

Answer

4>3>2>1

Answer

3>4>2>1

Question 3

Haemaccel contains -

Accepted Answer

Degraded gelatin

Answer

Calcium

Answer

Albumin

Answer

Sodium

Question 4

Warfarin induced skin necrosis is seen in?

Accepted Answer

Protein C deficiency

Answer

Protein S deficiency

Answer

Antithrombin III deficiency

Answer

Hemophilia

Question 5

Oral factor Xa inhibitor is:

Accepted Answer

Rivaroxaban

Answer

Bivalirudin

Answer

Dabigatran

Answer

Fondaparinux

Question 6

Coagulation testing is needed for:

Accepted Answer

Lepirudin (direct thrombin inhibitor)

Answer

Dabigatran (oral anticoagulant)

Answer

Enoxaparin (low molecular weight heparin)

Answer

Fondaparinux (synthetic pentasaccharide)

Question 7

All are used in management of overdosage of Fibrinolytics except?

Accepted Answer

DDAVP

Answer

Epsilon amino Caproic Acid

Answer

Tranexamic Acid

Answer

FFP

Question 8

Which of the following drugs is used for treatment of cancer associated thromboembolism?

Accepted Answer

LMW heparin

Answer

Direct factor Xa inhibitors

Answer

Warfarin

Answer

Anti-thrombin III inhibitors

Question 9

A patient with atrial fibrillation is prescribed warfarin. What is the PRIMARY factor that requires the most frequent monitoring to assess warfarin's anticoagulant effect?

Accepted Answer

INR (International Normalized Ratio)

Answer

Liver function

Answer

Potassium levels

Answer

Blood pressure monitoring

Question 10

A 32-year-old woman is diagnosed with iron deficiency anemia and is prescribed oral iron supplementation. Which form of iron is most commonly prescribed for oral administration?

Accepted Answer

Ferrous sulfate

Answer

Ferric citrate

Answer

Iron dextran

Answer

Ferrous fumarate

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?